Phase 1
Phase 2

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

Sponsor:

National Cancer Institute (NCI)

Code:

NCT06253494

Conditions

Endometrial Cancer

Cancer of Endometrium

Carcinoma of Endometrium

Endometrial Carcinoma

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

AdHER2DC vaccine

Pembrolizumab

N-803

Lenvatinib

PATHWAY HER2 (4B5) assay

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information